The safety profile seemed to be better than that of aldesleukin, an IL2 “wild-type” analog approved for the treatment of metastatic renal cell carcinoma and metastatic melanoma that is associated with the frequent occurrence of capillary leak syndrome necessitating close patient monitoring in a hospital setting (16). Here, IL2 is linked to metastatic melanoma.